Novartis
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
Swiss pharma major spanning cancer, cardiovascular, and gene therapies.
Coverage of Novartis is holding steady : 2 signals on the latest tracked day, level with its three-week baseline of 2, across 2 domains.
Novartis is steady by its own history. Its normal rhythm is about 2 signals a day across 2 domains. A real move would be a day at 3+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire.
What’s changed
- Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer · Fierce Pharma · 2026-08-03
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido · Fierce Biotech · 2026-07-31
- Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer · Fierce Biotech · 2026-07-14
- Icon inks Anthropic partnership to deploy Claude into clinical trials · Fierce Biotech · 2026-08-05
- Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims · Fierce Pharma · 2026-08-04
- Curium strikes up to $8B deal for radiopharma rival Lantheus · Fierce Biotech · 2026-08-04
What the reporting says
Across 26 tracked stories from 6 outlets, reporting on Novartis most often describes regulatory approvals (4), acquisition (3), military action (2), funding rounds (1), IPOs or listings (1), launches or releases (1).
It shows up alongside Pfizer (13), Astrazeneca (11), Bristol Myers Squibb (10), Merck (8), FDA (11), Eli Lilly (8).
Two steps out: AI (through FDA, 11 shared stories on the weaker link); China (through FDA, 11 shared stories on the weaker link); CMS (through FDA, 11 shared stories on the weaker link); Colorectal Cancer (through FDA, 11 shared stories on the weaker link).
Tracked since Jul 7, with coverage on 14 separate days — concentrated in Preprint and Biotech Pharma.